Research Article
Changes in Testing and Treatment Methods in Osteoporosis Care
Table 3
Postmatching test items, prescription details, and knowledge acquisition methods.
| | 2015 | 2020 | value |
| The number of doctors extracted | | 74 | 74 | |
| Examination Items | Xp of the thoracolumbar spine (%) | 45 (60.8) | 38 (51.4) | 0.25 | Bone mineral density of the lumbar spine and hip joint (%) | 30 (40.5) | 47 (63.5) | | MRI of spine (%) | 4 (5.4) | 2 (2.7) | 0.40 | No further examination (%) | 15 (20.3) | 8 (10.8) | 0.11 |
| Breakdown of bone metabolic markers | Any bone metabolic markers (%) | 59 (79.7) | 60 (81.1) | 0.84 | Urinary NTX (%) | 22 (29.7) | 9 (12.2) | | Serum NTX (%) | 4 (5.4) | 12 (16.2) | | BAP (%) | 12 (16.2) | 11 (14.9) | 0.82 | P1NP (%) | 23 (31.1) | 44 (59.5) | | TRACP-5b (%) | 33 (44.6) | 52 (70.3) | | ucOC (%) | 1 (1.4) | 3 (4.1) | 0.31 | DPD (%) | 0 (0) | 0 (0) | 1.00 |
| Blood test | 25(OH)D | 2 (2.7) | 19 (26.7) | p<0.001 |
| Treatment | Active vitamin D3 (%) | 50 (67.6) | 59 (79.7) | 0.09 | SERM (%) | 16 (21.6) | 18 (24.3) | 0.70 | Bisphosphonate (%) | 54 (73.0) | 39 (52.7) | 0.11 | Denosumab (%) | 5 (6.8) | 6 (8.1) | 0.75 | PTH preparation (%) | 9 (12.2) | 17 (23.0) | 0.08 | Romosozumab (%) | 0 (0) | 3 (4.1) | 0.08 | Vit K | 2 (2.7) | 0 (0) | 0.15 |
| Exercise therapy | Exercise therapy (%) | 37 (50.0) | 41 (55.4) | 0.51 |
| Nutritional guidance | Nutritional guidance (%) | 26 (35.1) | 32 (43.2) | 0.31 |
| Knowledge | Treatment experience (%) | 43 (58.1) | 40 (54.1) | 0.62 | Guidelines (%) | 25 (33.8) | 24 (32.4) | 0.86 | Lectures (%) | 16 (21.6) | 19 (26.7) | 0.56 | Textbooks (%) | 6 (8.1) | 5 (6.8) | 0.75 | Colleagues (%) | 2 (2.7) | 1 (1.4) | 0.56 | Medical representative (%) | 2 (2.7) | 1 (1.4) | 0.56 | No response (%) | 0 (0) | 2 (2.7) | 0.15 |
|
|
Statistical analysis included a Chi-square test. Xp: X-ray photography; MRI: magnetic resonance imaging, NTX: type I collagen cross-linked N-telopeptide; BAP: alkaline phosphatase; P1NP: procollagen I N-terminal propeptide; TRACP-5b: tartrate-resistant acid phosphatase 5b; PTH: parathyroid hormone; ucOC: undercarboxylated osteocalcin; DPD: deoxypyridinoline. Duplicate responses were obtained. |